We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$6.88B
AUM Growth
-$822M
Cap. Flow
-$1.07B
Cap. Flow %
-15.57%
Top 10 Hldgs %
44.23%
Holding
173
New
23
Increased
20
Reduced
28
Closed
33

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$65.2M
2
PRCT icon
Procept Biorobotics
PRCT
+$63.6M
3
FOLD
Amicus Therapeutics
FOLD
+$35.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$31.4M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$93.6M
2
NVRO
NEVRO CORP.
NVRO
+$73.1M
3
KDMN
Kadmon Holdings, Inc.
KDMN
+$60.8M
4
MDT icon
Medtronic
MDT
+$55.9M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.92%
2 Financials 0.85%
3 Industrials 0.17%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$599M 8.71%
3,387,745
+201,847
+6% +$32.5M
BBIO icon
2
BridgeBio Pharma
BBIO
$16.4B
$364M 5.28%
7,756,928
– –
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
$308M 4.47%
4,849,912
– –
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.04B
$283M 4.12%
11,489,772
+530,000
+5% +$12.5M
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
$254M 3.68%
26,559,443
+3,438,114
+15% +$35.2M
LABP
6
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$217M 3.15%
1,486,992
– –
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$214M 3.11%
1,956,940
-28,062
-1% -$2.91M
VBIV
8
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$171M 2.49%
1,834,749
– –
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$150M 2.18%
5,086,727
+443,632
+10% +$12.5M
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$121M 1.76%
7,471,798
+2,886,286
+63% +$31.4M
GBT
11
DELISTED
Global Blood Therapeutics, Inc.
GBT
$112M 1.63%
4,407,399
+254,710
+6% +$7.49M
NVTA
12
DELISTED
Invitae Corporation
NVTA
$112M 1.62%
3,923,741
-895,060
-19% -$26.2M
ZYME icon
13
Zymeworks
ZYME
$1.62B
$107M 1.55%
3,679,845
-625,755
-15% -$20.8M
CCCC icon
14
C4 Therapeutics
CCCC
$389M
$101M 1.47%
2,258,566
– –
OM icon
15
Outset Medical
OM
$86.4M
$98.4M 1.43%
132,709
-26,460
-17% -$18M
MGTX icon
16
MeiraGTx Holdings
MGTX
$1.08B
$91.6M 1.33%
6,948,277
– –
RAPT
17
DELISTED
RAPT Therapeutics
RAPT
$90.3M 1.31%
363,446
+53,988
+17% +$14.3M
ALDX icon
18
Aldeyra Therapeutics
ALDX
$97.1M
$87M 1.26%
9,903,879
– –
CRNX icon
19
Crinetics Pharmaceuticals
CRNX
$8.88B
$83.4M 1.21%
3,963,517
– –
AVIR icon
20
Atea Pharmaceuticals
AVIR
$370M
$79.2M 1.15%
2,259,224
– –
RXDX
21
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$78.6M 1.14%
3,314,032
– –
CHRS icon
22
Coherus Oncology
CHRS
$217M
$76.8M 1.12%
4,779,387
+81,775
+2% +$1.2M
ALBO
23
DELISTED
Albireo Pharma Inc
ALBO
$73.6M 1.07%
2,360,139
– –
RCKT icon
24
Rocket Pharmaceuticals
RCKT
$343M
$69.1M 1%
2,310,261
-441,342
-16% -$16.1M
PRCT icon
25
Procept Biorobotics
PRCT
$1.02B
$63.2M 0.92%
+1,656,990
New +$63.6M
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Perceptive Advisors held 173 positions worth $6.88B, down 11% from $7.71B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Perceptive Advisors withdrew a net $1.07B in Q3 2021, closing 33 positions and reducing 28 holdings. Its most notable exit was Kadmon Holdings, Inc., an estimated $60.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Icosavax, Inc. Common Stock worth $56.9M.

  • Perceptive Advisors's largest Q3 2021 buy was Icosavax, Inc. Common Stock: 1,922,549 shares worth $56.9M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q3 2021, an estimated $35.2M increase.
  • Perceptive Advisors's biggest Q3 2021 reduction was United Therapeutics, cutting an estimated $93.6M.
  • Perceptive Advisors fully exited Kadmon Holdings, Inc. in Q3 2021, selling an estimated $60.8M.
  • Perceptive Advisors's ten largest holdings make up 44% of its $6.88B portfolio in Q3 2021.
  • Perceptive Advisors opened 23 new positions and closed 33 in Q3 2021.
  • Perceptive Advisors's portfolio value fell 11% quarter-over-quarter to $6.88B.

Based on Perceptive Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.